Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

计划入组 7,100 人 · 首次发布于 2020 年 5 月 21 日

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

计划入组 49 人 · 首次发布于 2022 年 9 月 8 日

A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer

计划入组 24 人 · 首次发布于 2024 年 12 月 3 日

IT-62-B

IT-1208

IT-104

IT INTELLIGENT TREATMENT LLC

United States

SKIN & BARE IT, LLC

United States

Make It Happen Innovations LLC

United States

Pfizer's Hympavzi Receives FDA Approval for Hemophilia Treatment

AI-Driven Drug Discovery Accelerates with New Academic Alliance Targeting Protein Kinases

European Commission Approves Pfizer's Hympavzi for Haemophilia A and B